A PROSPECTIVE RANDOMIZED OPEN-LABEL BLINDED ENDPOINT EVALUATION (PROBE) PARALLEL GROUP STUDY COMPARING EDOXABAN (DU-176B) WITH ENOXAPARIN/WARFARIN FOLLOWED BY WARFARIN ALONE IN SUBJECTS UNDERGOING PLANNED ELECTRICAL CARDIOVERSION OF NONVALVULAR ATRIAL FIBRILLATION

Brief Description Of Study

The purpose of this study is to compare edoxaban with warfarin to see if it is safe and effective in preventing thromboembolism (formation of a clot [thrombus] in a blood vessel that breaks loose and is carried by the blood stream to block another vessel) and strokes which results when a brain blood vessel becomes blocked by a clot and in patients with AF who have undergone electrical cardioversion.

Clinical Study Identifier: 820126

Detailed Study Description

The purpose of this study is to compare edoxaban with warfarin to see if it is safe and effective in preventing thromboembolism (formation of a clot [thrombus] in a blood vessel that breaks loose and is carried by the blood stream to block another vessel) and strokes which results when a brain blood vessel becomes blocked by a clot and in patients with Atrial fibrillation who have undergone electrical cardioversion.

Contact research investigator to learn more about this study by filling out the form below.


To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: A PROSPECTIVE RANDOMIZED OPEN-LABEL BLINDED ENDPOINT EVALUATION (PROBE) PARALLEL GROUP STUDY COMPARING EDOXABAN (DU-176B) WITH ENOXAPARIN/WARFARIN FOLLOWED BY WARFARIN ALONE IN SUBJECTS UNDERGOING PLANNED ELECTRICAL CARDIOVERSION OF NONVALVULAR ATRIAL FIBRILLATION
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.